Drugs / Weifuchun
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05888675 | Jul 2016 → Oct 2020 | gastric cancer | ShuGuang Hospital | Completed | No outcome recorded |
| Phase 0 | NCT03814629 | Aug 2015 → Sep 2019 | chronic atrophic gastritis | ShuGuang Hospital | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06610266 | Feb 2025 → Oct 2026 expected | gastric intestinal metaplasia | Yongquan Shi | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05808010 | Jun 2023 → Apr 2025 | chronic atrophic gastritis | Shandong Provincial Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Weifuchun | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05888675 ↗ |
| Known as | WFC | “Weifuchun (WFC), a Chinese herbal prescription consisting of Red Ginseng, Isodon amethystoides and Fructus Aurantii, is commonly used in China to treat a variety of chronic...” PMID 34801051 ↗ Nov 2021 |
| Modality | Traditional medicine (herbal / TCM) | “Weifuchun (WFC), a Chinese herbal prescription consisting of Red Ginseng, Isodon amethystoides and Fructus Aurantii” PMID 34801051 ↗ Nov 2021 |
| Route | Oral | “Orally delivered tablets for 7 months.” NCT05808010 ↗ |